Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neoangiogenesis is the process of forming new blood vessels from existing ones, playing a crucial role in physiological processes like wound healing and pathological processes such as cancer. In tumors, neoangiogenesis supplies nutrients and oxygen that enable rapid tumor growth and metastasis. It is mediated by numerous growth factors (especially VEGF, but also PDGF, FGF, and others) and involves complex signaling between endothelial, stromal, and immune cells. Therapeutic strategies often target these molecular mediators to disrupt the abnormal blood supply essential for tumor survival and expansion. Neoangiogenesis is distinct from angiogenesis in that it more specifically refers to new vessel growth in the context of existing vasculature, typically in disease settings like malignancy or chronic inflammation.
Not applicable directly; mechanisms are via inhibition of molecular mediators (e.g., VEGF inhibitors, MMP inhibitors)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neoangiogenesis.